There are 3161 resources available
Agnostic ADCs (TROP2 and other combinations)
Presenter: Paolo Bironzo
Session: Antibody drug conjugates (ADCs) in lung cancer: Ready for prime time?
Resources:
Slides
Webcast
Cutaneous squamous cell carcinoma
Presenter: Mathilde Jalving
Session: Non-cutaneous melanoma and non-melanoma skin cancers: There is much more we can do
Resources:
Slides
Webcast
AI guided combinations using targeted therapy
Presenter: Udai Banerji
Session: Next generation of combinations in early clinical trials
Resources:
Slides
Webcast
Breast cancer
Presenter: Joseph Gligorov
Session: POWG 2: Optimal perioperative systemic treatment in different tumours
Resources:
Slides
Webcast
EU-CAYAS-NET IDE toolkit: Youth Cancer Europe
Presenter: Katie Rizvi
Session: Cancer patients and advocacy
Resources:
Slides
Webcast
810MO - Combination of mitoxantrone hydrochloride liposome with chidamide in patients with relapsed or refractory peripheral T cell lymphoma: A phase l/II study
Presenter: Zhiming Li
Session: Mini oral session 2: Haematological malignancies
Resources:
Abstract
Slides
Webcast
LBA33 - ICON9: International phase III randomized study to evaluate the efficacy of maintenance therapy with olaparib and cediranib or olaparib alone in patients with relapsed platinum-sensitive ovarian cancer following a response to platinum-based chemotherapy
Presenter: Shibani Nicum
Session: Mini oral session 1: Gynaecological cancers
Resources:
Abstract
Slides
Webcast
446MO - SYHA1813, a vascular endothelial growth factor receptor (VEGFR) 1-3/colony-stimulating factor 1 receptor (CSF1R) inhibitor, in patients with recurrent glioblastoma
Presenter: Wenbin Li
Session: Mini oral session: CNS tumours
Resources:
Abstract
Webcast
512O - Adjuvant aspirin treatment in PIK3CA mutated colon cancer patients: The phase III, prospective-randomized placebo-controlled multicenter SAKK 41/13 trial
Presenter: Ulrich Güller
Session: Proffered paper session 1: GI tumours, lower
Resources:
Abstract
Slides
Webcast
342MO - Metastatic hormone receptor-positive breast cancer outcomes in 628 patients with BRCA1, BRCA2, or PALB2 pathogenic variants: Real-world data analysis of genomics and targeted therapy sequencing
Presenter: Gerneiva Parkinson
Session: Mini oral session 1: Breast cancer, metastatic
Resources:
Abstract
Slides
Webcast